Back to Search
Start Over
Hepatotoxicity induced by coxibs: how concerned should we be?
- Source :
- Expert Opinion on Drug Safety. 15:1463-1475
- Publication Year :
- 2016
- Publisher :
- Informa UK Limited, 2016.
-
Abstract
- Introduction: The selective inhibitors of COX-2, coxibs, are nonsteroidal anti-inflammatory drugs (NSAIDs) that have much better gastrointestinal safety profile as compared with non-selective NSAIDs. In this review, we analyze both the epidemiological features of coxib-induced hepatotoxicity and the clinical impact of coxib-associated liver damage, based on literature data. Areas covered: We carried out a search of the databases MEDLINE (PubMed), LILACS and SCIELO, from December 1999 to January 2016, to retrieve studies exploring the real impact of coxibs in liver toxicity as compared to non-selective COX-2 inhibitor NSAIDs. Expert opinion: Although reliable data on the incidence of celecoxib- and etoricoxib-induced hepatotoxicity are lacking, because of cohort studies have been generally underpowered to detect hepatic events, coxibs have been scarcely related to hepatotoxicity. Hence, coxib-induced liver injury seems to be an uncommon event, yet exhibits a wide spectrum of damage. Increasing COX-2 drug selectivity, as for rofecoxib, valdecoxib, parecoxib, and lumiracoxib, has been associated with higher cardiovascular risk, as well as dermatological and serious hepatic reactions. The actual risk of liver toxicity from the currently approved coxibs compared with non-selective NSAIDs will be discussed. Finally, classical and novel molecular mechanisms of coxib-induced hepatotoxicity are also described. Fil: Bessone, Fernando. Provincia de Santa Fe. Ministerio de Salud y Medio Ambiente - Rosario. Hospital Provincial del Centenario; Argentina Fil: Hernandez, Nelia. Universidad de la República; Uruguay Fil: Roma, Marcelo Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Fisiología Experimental. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental; Argentina Fil: Ridruejo, Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno”; Argentina Fil: Mendizabal, Manuel. Hospital Universitario Austral; Argentina Fil: Medina Cáliz, Inmaculada. Universidad de Málaga; España Fil: Robles Díaz, Mercedes. Universidad de Málaga; España Fil: Lucena, M. Isabel. Universidad de Málaga; España Fil: Andrade, Raúl J.. Universidad de Málaga; España
- Subjects :
- 0301 basic medicine
CIENCIAS MÉDICAS Y DE LA SALUD
HEPATOTOXICITY
MEDLINE
CHOLESTASIS
Medicina Clínica
Pharmacology
Bioinformatics
HEPATITIS
03 medical and health sciences
0302 clinical medicine
Cholestasis
Animals
Humans
Medicine
COXIBS
Pharmacology (medical)
Liver damage
Liver injury
Hepatitis
Cyclooxygenase 2 Inhibitors
business.industry
Anti-Inflammatory Agents, Non-Steroidal
General Medicine
medicine.disease
Safety profile
SELECTIVE COX-2 INHIBITORS
030104 developmental biology
Celecoxib
030211 gastroenterology & hepatology
Medicina Critica y de Emergencia
Chemical and Drug Induced Liver Injury
ACUTE LIVER FAILURE
business
medicine.drug
Cohort study
Subjects
Details
- ISSN :
- 1744764X and 14740338
- Volume :
- 15
- Database :
- OpenAIRE
- Journal :
- Expert Opinion on Drug Safety
- Accession number :
- edsair.doi.dedup.....5350b055af405f8fa9442dcfa7dff92b